Characterization of *Escherichia Coli* Isolates from Patients with Urinary Tract Infections from Thabet Hospital-Tulkarm, Palestine

Ghaleb Adwan* & Buthainah Issa**

*Department of Biology & Biotechnology, Faculty of Science, An-Najah National University, Nablus, Palestine.

**Faculty of Graduate Studies, Department of Biological Science, An-Najah National University, P. O. Box 7-Nablus, Palestine.

* Corresponding author, E-mail: adwang@najah.edu

Received: (18/6/2014), Accepted: (11/3/2015)

Abstract

This study aimed to analyze phylogenetic groups, the presence of class I, II, III integrons and resistance phenotype in a collection of fifty *E. coli* strains isolated from urine specimens obtained from suspected cases with urinary tract infections at Thabet Hospital, During May-December 2012. The antibiotic susceptibility testing for these isolates was done by disk diffusion method. The phylogenetic groups and class I, II and III integrons were determined by multiplex PCR. Statistical analysis was done by using Mann-Whitney U-Test (Two-tailed), Chi-square ($\chi^2$) test or Fisher exact test. The results showed that 36 (72%) of the studied strains, belonged to group D, 13 (26%) strains to group A, and 1 (2%) strain belonged to group B1. Twenty one (42%) of *E. coli* strains carried class I integrons. Prevalence of class I integrons in group D and group A was 44.4% and 30.8%, respectively. There was no significant difference in the mean of antibiotic resistance score for strains belonged to group D and carried class I integrons and those belonged to group A and harbored the same integron class. Antibiotic resistance has
Characterization of Escherichia Coli from......


ranged from 24% for gentamicin to 100% for cefazolin and erythromycin. There is a significant difference in the mean of antibiotic resistance scores for strains belonged to group D (8.4) and group A (6.5) \((P = 6.2 \times 10^{-4})\). Results showed that 2 large clusters depend on resistance/sensitive of strains to fluoroquinolones. Association of trimethoprim/sulphamethoxazole resistance with the D group showed statistically significant difference \((P < 0.05)\) compared to group A. In conclusion, molecular analysis of 50 E. coli urine isolates exhibited a greater prevalence of class I integrons, a greater prevalence of phylogenetic group D, which possessed a higher resistance scores than group A. Urinary tract infections caused by such strains represent a clinical problem because of limited therapeutic options.

Keywords: UPEC, Integrons, antibiotic resistance scores, E. coli, Phylogenetic groups, Palestine.

من خاص

هدف هذه الدراسة إلى تحليل المجموعات التطورية، وإيجاد المجموعة الأولى والثانية والثالثة للانترجونات (integrons) والبحث عن مقاومة الأسركية الفولونية للمضادات الحيوية، في خمسة عينة معزولة من البول، والتي تم الحصول عليها من الحالات المشتبه فيها بوجود التهابات المسالك البولية في مستشفى ثابت، خلال شهر أيار إلى كانون الأول 2012. وتم إجراء فحص الحساسية للمضادات الحيوية لهذه السلالات عن طريق انتشار القرص. المجموعات التطورية والمجموعة الأولى والثانية والثالثة للانترجونات تم تدحيدها باستخدام تقنية سلسلة تفاعل البلمرة المتعدد (Multiplex PCR) وامكانيها - وتيتي (Mann-Whitney U-Test) U- Test (Mann-Whitney U-Test) U- Test. وظهر النتائج أن 36% (72%) من هذه السلالات تنتمي إلى مجموعة D، و26% من السلالات تنتمي إلى المجموعة A، في حين تنتمي إحدى السلالات (2%) إلى المجموعة B1. وكانت إحدى وعشرون (42%) من سلالات الأسركية الفولونية تحمل المجموعة الأولى للانترجونات، 44.4% من سلالات المجموعة D، 30.8% من سلالات المجموعة A. كانت تحمل المجموعة الأولى للانترجونات، وأظهرت النتائج أيضاً أنه لا يوجد فرق إحصائي معنوي في متوسط سجل النقطة لمقاومة المضادات الحيوية للسلالات التي تنتمي إلى المجموعة D، وتحمل المجموعة الأولى للانترجونات (A) التي تنتمي إلى المجموعة D، وتحمل المجموعة الأولى للانترجونات (A). تناولت المجموعة الأولى للانترجونات وترأحت المقاومة للمضادات الحيوية من 24% للجيناتين إلى 100% لسيفازولين والأزيثروميسين، وتبين أن هناك فرقة كبيرة في متوسط سجل النقطة لمقاومة المضادات الحيوية للسلالات التي تنتمي إلى المجموعة D (8.4) و A (6.5).
Introduction

*Escherichia coli* (*E. coli*) is considered as one of the most abundant facultative anaerobic bacteria of the human and of many animals intestinal microflora. It is one of the most common clinical isolate recovered in clinical microbiology laboratories. Strains of this microorganism are classified into three major groups according to their biological significance to humans: harmless commensal strains, intestinal pathogenic strains, and extraintestinal pathogenic strains, (*Russo & Johnson, 2000*). *E. coli* is considered the most frequent cause of urinary tract infections (UTI). Other different infections in humans are also included. It is also responsible for an enormous burden of morbidity, mortality, and health care costs (*Russo & Johnson, 2000*).

Uropathogenic *E. coli* (UPEC) strains are the most commonly isolated organisms in community-acquired UTIs (70 to 90%) and among the most commonly isolated in nosocomially acquired UTIs (50%) including catheter-associated UTIs (CAUTI). *E. coli* has been identified as the causative agent in 90% of all case of UTI in ambulatory patients (*Jacobsen, & et al. 2008*). The clinical management of UTIs has become very complicated due to the emergence of resistance to most commonly used antimicrobial agents, particularly among UPEC strains (*Karaca, & et al. 2005*). A noticeable decrease in the occurrence of UPEC strains that are sensitive to cephalosporins, quinolones, fluoroquinolones, and trimethoprim, which has special clinical importance because of the
limited therapeutic options available was reported (Piatti, & et al. 2008). Integrons appear to play an important role in horizontal dissemination of genetic elements and accumulation of resistance genes in *E. coli* derived from animals and humans (Solberg, & et al. 2006). A strong association between the presence of integrons and antimicrobial resistance has been established by recent studies on UPEC (Solberg, & et al. 2006; Muhammad, & et al. 2011).

Most human extraintestinal *E. coli* infections, including those involving antimicrobial resistant strains are caused by the members of a few limited number of distinctive *E. coli* lineages, termed extraintestinal pathogenic *E. coli* (ExPEC) which have a special ability to cause disease at extraintestinal sites when they exit their usual reservoir in the host’s intestinal tract (Manges & Johnson, 2012). Phylogenetic studies have shown that *E. coli* clones can be defined into 4 major phylogenetic groups, designated A, B1, B2 and D. Typing of pathogenic *E. coli* is based on certain genes or DNA fragments might be specific phylogenetic group markers. These include a gene required for heme transport in EHEC O157:H7 (*chuA*), a gene initially identified in the recent complete genome sequence of *E. coli* K-12, the function of which is unknown (*yjaA*) and an anonymous DNA fragment designated *TspE4.C2* (Clermont, et al. 2000).

Strains that cause extraintestinal infections mostly belonged to groups B2 and/or D (Russo & Johnson, 2000; Duriez, & et al. 2001; Johnson, & et al. 2005a; Piatti, & et al. 2008; Petkovsek, & et al. 2009; Lee, & et al. 2010; Bashir, & et al. 2011; 2012), where most commensal and less virulent strains belong mostly to group A or B1 (Russo & Johnson, 2000; Duriez, & et al. 2001). Other studies reported a high proportion of group B2 or D strains in the intestinal microflora of humans (Zhang, & et al. 2002; Nowrouzian, & et al. 2005; Lee, & et al. 2010). Association between *E. coli*, phylogenetic groups and drug resistance was reported by several researchers (Johnson, & et al. 2005b; Horcajada, & et al., 2005; Moreno, & et al. 2006; Piatti, & et al. 2008; Kawamura-Sato, & et al. 2010; Bashir, & et al. 2011; Molina-López, & et al., 2011).
The aims of this study were to investigate the pattern of antimicrobial resistance, phylogenetic groups and integron classes in a collection of *E. coli* strains isolated from suspected cases of urinary tract infections at Thabet Hospital. In addition, to investigate associations between multi-drug resistance, existence of integrons and Phylogenetic group. Integrons detection has not been investigated previously from *E. coli* in Palestine.

**Materials and Methods**

**Sample collection**

Fifty isolates of *E. coli* were recovered from urine specimens obtained from suspected cases of urinary tract infections of inpatients and outpatients at Thabet Hospital, Tulkarm-Palestine, during May-December 2012. These isolates were identified in the laboratory of Thabet Hospital and also were confirmed in the microbiology laboratories at An-Najah National University-Nablus. The isolates were cultured on MacConkey and/or EMB agars, Gram stain, motility test and biochemical tests such as IMViC tests and H₂S production were carried out on all isolates.

**Antibiotic resistance**

Antimicrobial susceptibility was determined according to the Clinical and Laboratory Standard Institute (CLSI) using the disk diffusion method (CLSI, 2010). All *E. coli* isolates were examined for resistance to tetracycline (TE) 30µg, streptomycin (S) 10µg, gentamicin (CN) 10µg, kanamycin (K) 30µg, nalidixic acid (NA) 30µg, norfloxacin (NOR) 10µg, ciprofloxacin (CIP) 10µg, ofloxacin (OFX) 5µg, Levofloxacin (LEV) 5µg, ceftriaxone (CRO) 30µg, ceftazidime (CAZ) 30µg, cefazolin (CZ) 30 µg, trimethoprim/sulfamethoxazole (SXT) 1.25 /23.75µg and erythromycin (E) 15 µg. All antibiotics used in this study were purchased from Oxoid. Zones of inhibition were determined in accordance with procedures of the Clinical and Laboratory Standard Institute (CLSI, 2010).
DNA extraction

*E. coli* DNA was prepared for PCR according to the method described previously (Adwan, & *et al.* 2013). Briefly, cells were scraped off an overnight nutrient agar plate with a sterile loop, washed with 1 ml of 1X Tris-EDTA buffer (10 mM Tris-HCl, 1 mM EDTA [pH 8.0]). The pellet was then resuspended in 0.5 ml of sterile distilled H₂O and boiled for 10-15 min. The cells then were incubated on ice for 10 min. The debris was pelleted by centrifugation at 11,500 X g for 5 min. DNA concentration was determined using a spectrophotometer and the samples were stored at -20ºC until use.

Polymerase chain reaction

**Phylogenetic classification**

Strains were assigned to one of the four *E. coli* phylogenetic groups (A, B1, B2 and D) using a triplex PCR based on the presence or absence of three DNA fragments: chuA, yjaA, and TspE4C2 (Clermont, & *et al.* 2000). The primer pairs used were chuA.1 (5'-GAC GAA CCA ACG GTC AGG AT-3') and chuA.2 (5'-TGC CGC CAG TAC CAA AGA CA-3'); yjaA.1 (5'-TGA AGT GTC AGG AGA CGC TG-3') and yjaA.2 (5'-ATG GAG AAT GCG TTC CTC AAC-3'); and TSPE4.C2.1 (5'-GAG TAA TGT CGG GGC ATT CA-3') and TSPE4.C2.2 (5'-CAG GCC AAC AAA GTA TTA CG-3'); these generated fragments of 279, 211 and 152 bp respectively. Combination of PCR products allowed phylogenetic group determination of *E. coli* isolates as described previously (Clermont, & *et al.* 2000).

Each PCR reaction mix (25 μl) was performed using 12.5 μl of PCR premix with MgCl₂ (ReadyMix™ Taq PCR Reaction Mix with MgCl₂, Sigma), 0.4 μM of each primer, and 3 μl DNA template. DNA amplification was carried out using the thermal cycler (Mastercycler personal, Eppendorf, Germany) according to the following thermal conditions: initial denaturation for 4 min at 94ºC followed by 30 cycles of denaturation at 94ºC for 30 s, annealing at 55ºC for 30 s and extension at 72ºC for 30 s, with a final extension step at 72ºC for 5 min. The PCR products (10 μl) were analyzed by electrophoresis on 1.5% agarose gel to determine the phylogenetic group.
Detection class I, II and III integrons

All *E. coli* isolates were screened for the presence of integrase genes *intI1* and *intI2* and *intI3* using primers described previously (Shibata, & *et al.* 2003). Primer *intI1* (forward: 5′-GCA TCC TCG GTT TTC TGG-3′, reverse: 5′-GCT GTG GCG GGC TTC GTG-3′ expected size amplicon is 457bp), *intI2* (forward: 5′-CAC GGA TAT GCG ACA AAA AGG T-3′, reverse: 5′-GTA GCA AAC GAG TGA CGA AAT G-3′ expected size amplicon is 789bp) and *intI3* (forward: 5′-ATC TGC CAA ACC TGA CTG-3′, reverse: 5′-CGA ATG CCC CAA CAA CTC-3′ expected size amplicon is 922bp). PCR reaction mix was performed as described in phylogenetic group determination. DNA amplification was carried out using the thermal cycler (Mastercycler personal, Eppendorf, Germany) according to the following thermal conditions: initial denaturation for 4min at 94°C followed by 35 cycles of denaturation at 94°C for 40 s, annealing at 56°C for 40 s and extension at 72°C for 40 s, with a final extension step at 72°C for 5 min. The PCR products (10 μl) were analyzed by electrophoresis on 1.5% agarose gel.

**Statistical analysis**

Comparisons of proportions were tested using the Chi² (χ²) test or Fisher exact test. Comparisons of aggregate antibiotic resistance scores were done by using the Mann-Whitney U-test. *P* < 0.05 values were considered statistically significant.

**Results**

Analysis of data showed that the majority of the studied isolates, namely 36 (72%) strains belonged to group D. Thirteen strains (26%) were assigned to group A, while 1 strain (2%) was belonged to group B1 (Figure 1). There was a significant difference between the prevalence of these phylogenetic groups at *P* < 0.001.
Figure (1): Triplex PCR profiles specific for *E. coli* phylogenetic groups. Lanes 1, 2, 4, 5, 8, 10, 11 and 12 belonged to phylogenetic group D; lanes 3, 7 and 9 belonged to phylogenetic group A; lane 6 belonged to phylogenetic group B1, and lane L: Ladder.
Twenty one (42%) of E. coli strains contained class I integrons. Class II and III were not detected in these strains. Strains carried class I integrons showed a higher mean antibiotic resistance score (9.8) than those without class I integrons (6.6). The comparison of intra-group percentages revealed that class I integrons were most prevalent (44.4%) in group D isolates compared to 30.8% in group A. These results showed no significant difference in the mean antibiotic resistance score (10) for strains belonged to group D and carried class I integrons and those belonged to group A (9.5).

Seven different classes of antibiotics were used including: Quinolones (nalidixic acid), Cephalosporines (ceftaxoxine, ceftazidime, cefazolin), Tetracyclines (tetracycline), Fluoroquinolones (ofloxacin, ciprofloxacin, levoflaxacin, norflaxacin), Aminoglycosides (streptomycin, kanamycin, gentamicin), Sulfonamides (trimethoprim/sulphamethoxazole) and Macrolides (erythromycin). The rates of resistance of E. coli isolates to different antibiotics tested are presented in Table 1. Antibiotic resistance has ranged from 24% for gentamicin to 100% for cefazolin and erythromycin. Forty resistance patterns were observed in the UPEC isolates with profile streptomycin-kanamycin-cefazolin-erythromycin, being the most predominant (n=5) indicating a striking diversity of resistance patterns among uropathogenic strains in this hospital. Also results showed that 98% of strains were multidrug resistant (MDR). Gentamicin, norflaxacin and levoflaxacin were the most effective drugs in general. Group D isolates showed high resistant rate compared with isolates belonged to group A. The correlation between the median antibiotic resistance scores and the phylogenetic group was examined. The median antibiotic resistance scores were 8.4 and 6.5 for strains belonged to group D and group A, respectively. Differences were statistically significant ($P = 6.2 \times 10^{-4}$). The prevalence of antibiotic resistance tested in each strain ranged from 14.3% to 100%. It was found that 61.5% (8/13) of strains belonged to group A were resistant to 5 or less antibiotics, while 66.7% (24/36) of strains belonged to phylogenetic group D were resistant to 6 or more antibiotics. Based on resistant patterns to fluoroquinolones isolates were grouped into 2 large clusters. The clustering pattern was
independent of phylogenetic groups (Figure 2). The results also showed strong association of trimethoprim/sulphamethoxazole resistance with the D group \( P < 0.05 \) (Table 1). Among fluoroquinolones and/or quinolones-resistant strains, the frequencies of groups D and A, were 75.0% (27/36) and 61.5% (8/13), respectively.

**Figure (2):** Dendrogram of 50 uropathogenic *E. coli* strains isolated from urine samples based on the UPGMA method derived from analysis of the antibiotic resistance profile, phylogenetic groups and class I integrons.

C: Cluster; R: resistant; S: sensitive.
### Table (1): Antibiotic resistance of 50 *E. coli* urinary isolates recovered from Thabet Hospital, Tulkarm, Palestine.

<table>
<thead>
<tr>
<th>Group</th>
<th>Antibiotic</th>
<th>Resistant strains</th>
<th>Prevalence of antibiotic resistance between groups*</th>
<th>Aggregate antibiotic resistance scores (median)*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>No. of samples</td>
<td>%</td>
<td>D (n=36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A (n=13)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>D 8.4 (304/36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A 6.5 (84/13)</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>Tetracycline</td>
<td>31</td>
<td>62</td>
<td>66.7% (24/36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>46.2% (6/13)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.6 (237/36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.3 (56/13)</td>
</tr>
<tr>
<td>Quinolones</td>
<td>Nalidixic Acid</td>
<td>34</td>
<td>68</td>
<td>72.2% (26/36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>53.8% (7/13)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7.3 (261/36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.5 (59/13) * ****</td>
</tr>
<tr>
<td>Cephalosporines</td>
<td>Ceftriazone</td>
<td>23</td>
<td>64</td>
<td>52.8% (19/36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30.8% (4/13)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7.1 (257/36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.9 (38/13) * ****</td>
</tr>
<tr>
<td></td>
<td>Cefazolin</td>
<td>17</td>
<td>34</td>
<td>53.8% (14/36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>23.1% (3/13)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.5 (163/36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.2 (28/13) * ****</td>
</tr>
<tr>
<td></td>
<td>Cefazolin</td>
<td>50</td>
<td>100</td>
<td>100% (36/36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100% (13/13)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8.8.4 (304/36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.5 (84/13)</td>
</tr>
</tbody>
</table>

---

*An - Najah Univ. J. Res. (N. Sc.) Vol. 30, 2016*
Characterization of *Escherichia Coli* from ......

... Continue table (1)

<table>
<thead>
<tr>
<th>Group</th>
<th>Antibiotic</th>
<th>Resistant strains</th>
<th>Prevalence of antibiotic resistance between groups (^a)</th>
<th>Aggregate antibiotic resistance scores (median) (^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>No. of samples</td>
<td>%</td>
</tr>
<tr>
<td>Fluoroquinolones</td>
<td>Ciprofloxacin</td>
<td></td>
<td>21</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>Levofloxacin</td>
<td></td>
<td>19</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>Norfloxacin</td>
<td></td>
<td>18</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Ofloxacin</td>
<td></td>
<td>22</td>
<td>44</td>
</tr>
<tr>
<td>Aminoglycosides</td>
<td>Kanamycin</td>
<td></td>
<td>29</td>
<td>58</td>
</tr>
</tbody>
</table>

\(^a\) Numbers in parentheses indicate the number of resistant strains out of the total number of samples.
<table>
<thead>
<tr>
<th>Group Antibiotic</th>
<th>Resistant strains</th>
<th>Prevalence of antibiotic resistance between groups\textsuperscript{a}</th>
<th>Aggregate antibiotic resistance scores (median)\textsuperscript{a}</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of samples</td>
<td>% (n=36)</td>
<td>D (n=36)</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>12</td>
<td>24</td>
<td>25% (9/36)</td>
</tr>
<tr>
<td>Streptomycin</td>
<td>37</td>
<td>74</td>
<td>77.8% (28/36)</td>
</tr>
<tr>
<td>Macrolides</td>
<td>50</td>
<td>100</td>
<td>100% (36/36)</td>
</tr>
<tr>
<td>Sulfonamides</td>
<td>32</td>
<td>64</td>
<td>75% (27/36)</td>
</tr>
</tbody>
</table>

\textsuperscript{a}One isolate of group B1 is not included; \textsuperscript{b}Mann-Whitney U-test.

\textsuperscript{**} significant difference at $P < 0.05$, \textsuperscript{***} significant difference at $P < 0.01$, \textsuperscript{****} significant difference at value $P < 0.001$ ($\chi^2$ test and Fisher exact test).

---

Discussion

Urinary tract infections are one of the most common infectious diseases and remain a major cause of morbidity and mortality. *E. coli* strains are considered as a major causative of such infections. The pathogen has main 4 phylogenetic groups: A, B1, B2 or D. Extraintestinal pathogenic *E. coli* are phylogenetically and epidemiologically distinct from commensal and diarrheagenic strains. According to human, commensal strains usually derive from phylogenetic groups A and B1, while most of ExPEC strains usually belong to the B2 and D groups.

This study showed that the majority of *E. coli* strains from patients with UTIs were belonged to phylogenetic group D. In this respect, our findings were inconsistent with other studies concerning phylogenetic groups in UPEC (Johnson, & *et al.* 2005a; Takahashi, & *et al.* 2006; Molina-López, & *et al.* 2011; Kawamura-Sato, & *et al.* 2010; Ejrnæs, & *et al.* 2011; Bashir, & *et al.* 2011; Gündoğdu, & *et al.* 2011; Bashir, & *et al.* 2012), were group B2 was the predominant phylogenetic group. However, our findings were consistent with a previous report were D group was the dominant group (Abdallah, & *et al.* 2011). Recent study in the area (Adwan, & *et al.* 2014), showed that 61% of *E. coli* urine isolates were belonged almost equally to phylogenetic groups B2 and D. Such differences in the distribution of the phylogenetic groups among the strains of geographically different populations may be affected by different factors such as geographical, climatic conditions, dietary factors, the use of antibiotics and host genetic factors.

Multi-drug resistance encoded by resistance genes clustered in integrons, which are potentially mobile genetic elements, considered to be involved in the transfer of multi-drug resistance among *E. coli*. The finding of high prevalence of class I integrons in the current study is consistent with previous reports (Japoni, & *et al.* 2008; Muhammad, & *et al.* 2011; Al-Assil, & *et al.* 2013). Urinary tract infections caused by such strains with high prevalence of co-occurrence of class I integrons and high antimicrobial resistance levels represent a clinical problem because of limited therapeutic options. The finding of 42% of isolates harboring only class I integrons is inconsistent with that reported previously.
(Rezaee, & et al. 2011), were only 27.1% of MDR isolates carried class I and class II integrons.

The antimicrobial resistance among UPEC has increased dramatically worldwide (Johnson, & et al. 2003). In our study, the most prevalent resistances were to nalidixic acid, ceftriaxone, cefazolin, tetracycline, ofloxacin, ciprofloxacin, streptomycin, kanamycin, trimethoprim/sulphamethoxazole and erythromycin. These antibiotics were and still the best therapeutic choices and therefore higher resistance prevalences are not surprising (Petkovsek, & et al. 2009). The study also showed that 98% strains of *E. coli* were multidrug resistant and isolates from UTIs showed higher resistance rates to all antibiotics. These were consistent with new report published from Palestine (Adwan, & et al. 2014), which showed that *E. coli* strains isolated from patients with UTIs had high resistance to different antibiotics. This high rate of resistance is most likely due to high antibiotic selective pressure resulting from inappropriate use of these antimicrobial agents in various clinical setting. The finding of high prevalence of integrons regardless of the phylogenetic group was reported by (Saeed, & et al. 2009). While those strains of *E. coli* under very low selective pressure, resistance emerges without integrons (Skurnik, & et al. 2009). Thus, the emergence of resistant strains in our area might be promoted by the lack of proper use of an antibiotics and/or the availability of antibiotics sold over the counter. These results were in contrast report published recently (Ejrnæs, & et al. 2011), which showed that *E. coli* strains collected from recurrent UTIs characterized by a low level of resistance. Also these finding results were consistent with previous results (Molina-López, & et al. 2011; Muhammad, & et al. 2011; Ferjani, & et al. 2012), which showed that UPEC strains expressed highest resistance rates to different antimicrobial agents. In addition, these results were consistent with a previous reports (Bashir, & et al. 2011), which showed that all the isolates were multiple drug resistant (MDR). Data of this research were consistent with previous reports (Bashir, & et al. 2011), which showed that phylogenetic group D isolates were more drug resistant as compared with phylogenetic group A. The emergence of 40 drug resistance patterns showed high variability among local UPEC isolates.
Although our study is comprised of a relatively small number of samples and therefore faces limitations in statistical analysis, even it provides important information about the phylogenetic background of uropathogenic *E. coli* from Northern Palestine. In conclusion, the molecular analysis of 50 *E. coli* urine isolates exhibited a greater prevalence of class I integrons, a greater prevalence of phylogenetic group D, which possessed higher resistance scores than group A. Urinary tract infections caused by such strains represent a clinical problem because of limited therapeutic options.

**Acknowledgments**

The authors are grateful to Dr. Nael Abu-Hasan, An-Najah National University, Faculty of Science, Department of Biology and Prof. Hamdi Aljabali, An-Najah National University, Faculty of Arts, Arabic Department, for language revision.
References (Arabic & English)


Characterization of *Escherichia Coli* from ......


Characterization of *Escherichia Coli* from ... 


background and quinolone and fluoroquinolone resistance. Journal of Clinical Microbiology, 46, 480-487.


genes, and O-serogroup Profiles. Journal of Clinical Microbiology, 44, 4589-4592.
